SALT LAKE CITY, UT, Feb. 27, 2018 (GLOBE NEWSWIRE) — Amedica Corporation (NASDAQ:AMDA), an innovative biomaterial company that develops and commercializes silicon nitride for biomedical applications, is pleased to announce that it has been invited to present at the 29th Annual Scientific Meeting of the Australian Spine Society. The forum, attended by spine surgeons throughout Australia, is a new opportunity in light of Australian regulatory approval in 2017 for Amedica products. Amedica’s presentation is titled “Effect of Surface Topography on the Bacteriostatic and Osseointegration Behavior of Silicon Nitride” and summarizes an independent investigation supporting the unique antibacterial properties of silicon nitride.
“Australia is of particular interest since the first spinal fusion with silicon nitride was performed by Australian surgeons 30 years ago. The meeting is a great platform to introduce Amedica’s silicon nitride to Australian surgeons, and to build new sales in that market. This is an exciting opportunity to leverage scientific data and knowledge toward identifying new markets and sales opportunities for our products. ” said Dr. Sonny Bal, MD, MBA, JD, PhD; Chairman and CEO of Amedica.
About Amedica Corporation
Amedica is focused on the development and application of spinal interbody implants made with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing implants for other biomedical applications, such as wear- and corrosion-resistant hip and knee bearings, and dental implants. The Company’s products are manufactured in its FDA registered and ISO 13485 certified manufacturing facility, and it has a partnership with Kyocera, one of the world’s largest ceramic manufacturers. Amedica’s FDA-cleared and CE-marked spine products are currently marketed in the U.S. and select markets in Europe and South America through its distributor network, as well as OEM and private label partnerships.
For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Such statements include statements regarding the building of new sales in the Australian market. A discussion of those risks and uncertainties can be found in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K/A, filed with the Securities and Exchange Commission (SEC) on December 27, 2017, and in Amedica’s other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.
Contacts: Amedica IR 801-839-3502 IR@amedica.com
Source: Amedica Corporation
This article appears in: News Headlines
Referenced Stocks: AMDA